文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌围手术期dd-MVAC与GC方案随机III期试验:毒性及病理反应分析

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
PubMed 文献 · Eur Urol · 2020-08-28

GETUG/AFU V05 VESPER试验随机纳入500例肌层浸润性膀胱癌患者,比较围手术期dd-MVAC与GC方案。新辅助组中dd-MVAC的器官局限率显著更高(77% vs 63%,p=0.001),但两组完全病理缓解率无显著差异(42% vs 36%,p=0.2);dd-MVAC组≥3级乏力及胃肠道不良反应更常见。

要点

  • dd-MVAC组器官局限率显著高于GC组(77% vs 63%,p=0.001)
  • 完全病理缓解率两组无显著差异(42% vs 36%,p=0.2)
  • dd-MVAC组≥3级乏力和胃肠道毒性更常见,但总体可管理

核心结论

  • 围手术期dd-MVAC方案毒性可管理,但≥3级乏力和胃肠道不良反应较GC更常见。
  • dd-MVAC组局部控制率更高(完全病理缓解、肿瘤降期或器官局限),需待无进展生存期数据确认。

研究设计与样本

  • 随机III期试验,2013年2月至2018年3月从28个中心随机纳入500例肌层浸润性膀胱癌患者。
  • 患者接受每2周一次dd-MVAC共6周期或每3周一次GC共4周期,分新辅助和辅助两组。

主要发现

  • 新辅助组中dd-MVAC组218例、GC组219例;dd-MVAC组60%完成6周期,GC组84%完成4周期。
  • 新辅助组dd-MVAC和GC分别有199例(91%)和198例(90%)接受手术。
  • 完全病理缓解(ypT0pN0)dd-MVAC组84例(42%)、GC组71例(36%),p=0.2。
  • 器官局限(<ypT3pN0)dd-MVAC组154例(77%)、GC组124例(63%),p=0.001。
  • ≥3级血液学毒性dd-MVAC组129例(52%)、GC组134例(55%);≥3级胃肠道反应dd-MVAC组更常见(p=0.003),≥3级乏力亦更常见(p<0.001)。

关键数值与推荐

  • 完全病理缓解率dd-MVAC组42% vs GC组36%(p=0.2)。
  • 器官局限率dd-MVAC组77% vs GC组63%(p=0.001)。
  • ≥3级血液学毒性dd-MVAC组52% vs GC组55%。
  • dd-MVAC组胃肠道≥3级不良反应更常见(p=0.003),乏力≥3级更常见(p<0.001)。
  • dd-MVAC组局部控制率更高(p=0.021)。

临床怎么用

  • 围手术期化疗选择dd-MVAC时需关注乏力和胃肠道毒性管理。
  • dd-MVAC可能提高器官局限率,但需结合无进展生存期数据综合决策。

局限性

  • 主要终点(3年无进展生存期)未报告,需等待2021年中期数据确认。
  • 辅助组化疗完成率较低(dd-MVAC组40%完成6周期,GC组60%完成4周期)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC). Retrospective studies or prospective phase II trials have been reported to use dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC). As dd-MVAC has shown higher response rates in metastatic disease, better efficacy is expected in the perioperative setting. OBJECTIVE: We designed a randomized phase III trial to compare the efficacy of dd-MVAC or GC in MIBC perioperative (neoadjuvant or adjuvant) setting. DESIGN, SETTING AND PARTICIPANTS: A total of 500 patients were randomized from February 2013 to March 2018 in 28 centers and received either six cycles of dd-MVAC every 2 wk or four cycles of GC every 3 wk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint (progression-free survival at 3 yr) was not reported. We focused on secondary endpoints: chemotherapy toxicity and pathological responses. RESULTS AND LIMITATIONS: In the neoadjuvant group, 218 patients received dd-MVAC and 219 received GC. Of the patients, 60% received six cycles in the dd-MVAC arm and 84% received four cycles in the GC arm; 199 (91%) and 198 (90%) patients underwent surgery, respectively. Complete pathological response (ypT0pN0) was observed in 84 (42%) and 71 (36%) patients, respectively (p=0.2). An organ-confined status (<ypT3pN0) was obtained in 154 (77%) and 124 (63%) patients, respectively (p=0.001). In the adjuvant group, 40% of patients received six cycles in the dd-MVAC arm and 60% received four cycles in the GC arm. Most of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 toxicities concerned hematological toxicities, reported for 129 (52%) patients in the dd-MVAC group and 134 (55%) patients in the GC group. Gastrointestinal (GI) grade ≥3 disorders were more frequently observed in the dd-MVAC arm (p=0.003), as well as asthenia of grade ≥3 (p<0.001). CONCLUSIONS: The toxicity of dd-MVAC was manageable with more severe asthenia and GI side effects than that of GC in perioperative chemotherapy. A higher local control rate (complete pathological response, tumor downstaging, or organ confined) was observed in the dd-MVAC arm (p=0.021). However, such data have to be confirmed on progression-free survival, with primary endpoint data expected in mid-2021. PATIENT SUMMARY: The authors have designed a randomized phase III controlled study comparing the efficacy of gemcitabine and cisplatin, and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) in patients for whom chemotherapy has been decided, before or after radical cystectomy. Higher toxicity regarding asthenia and gastrointestinal side effects along with a better bladder control rate were observed in the dd-MVAC arm. However, such data have to be confirmed on progression-free survival, with primary endpoint data expected in mid-2021.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pfister C, Gravis G, Fléchon A, et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol. 2020. PMID: 32868138. doi:10.1016/j.eururo.2020.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。